Leukaemia

#FDA #Investigational New Drug (IND) #Leukaemia #Lymphoma

FDA grants IND clearance to novel BTK degrader 

A novel treatment for relapsed/refractory B-cell malignancies has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA).  APG-3288, developed by biopharmaceutical company Ascentage Pharma, is a novel next-generation BTK-targeted protein degrader. The candidate is designed to induce rapid, potent, highly selective, and sustained degradation of both wild-type BTK… Read More

#News #Regulatory

Acute lymphoblastic leukemia
#ASH 2025 #Clinical trial #Leukaemia #Oncology

Pirtobrutinib more effective than ibrutinib, study finds 

A study into treatments for chronic lymphocytic leukaemia and small lymphocytic leukaemia (CLL/SLL) has found that Jaypirca (pirtobrutinib) is more effective than Imbruvica (ibrutinib).  The Phase III, first-of-its-kind BRUIN CLL-314 trial found that pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib. Pirtobrutinib, developed by Eli… Read More

#Cancer Research #News

Chronic myeloid leukaemia
#ASH 2025 #Leukaemia #Oncology

Drug shows ‘unprecedented’ response in chronic myeloid leukaemia 

Oncology company Terns Pharmaceuticals has announced encouraging results showing its candidate could be a best-in-class treatment for relapsed and refractory chronic myeloid leukaemia (CML).   The Phase I trial of TERN-701 showed a 64% major molecular response (MMR) achievement rate across all efficacy evaluable patients, also proving its safe and… Read More

#Cancer Research #News

#Acute Myeloid Leukaemia #Cancer research #Leukaemia #Oncology #Syndax Pharmaceuticals

Leading the charge in cancer care

DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of Syndax, about its work on developing therapeutics for challenging cancer targets.    RA: What are the unmet needs in relapsed or refractory acute leukaemia. How great is this unmet need in paediatric patients?   MM: Syndax is initially focused on two… Read More

#Exclusive Content

Pancreatic cancer
#Cancer research #Leukaemia #Oncology #Proteomics

Discovery of ‘handbrake’ enzyme offers cancer breakthrough 

Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance.  The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular… Read More

#Cancer Research #News

#Cancer research #Drug discovery #Leukaemia

CAR-T therapy could be effective cancer treatment, study suggests

CAR-T therapy could be an effective treatment for leukaemia, preclinical data published by biotechnology company Gyala Therapeutics suggests.  The data emerged from a study highlighting the use of CAR-T therapy, GYA01, to treat acute myeloid leukaemia (AML) and T-cell acute lymphoblastic leukaemia (T-ALL). The study is the… Read More

#Cancer Research #News

European Commission
#Autolus #CAR-T #Cell therapy #European Commission #Leukaemia #Oncology

Autolus Therapeutics’ CAR-T therapy gets EU green light

The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).  The EC approval was based on the results of the FELIX study, an open-label, multi centre, single arm… Read More

#News #Regulatory

Leukaemia
#AstraZeneca #Blood cancer #European Commission #Leukaemia #Oncology

Fixed-duration Calquence-based regimens approved in EU

A fixed-duration regimen of AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for previously untreated chronic lymphocytic leukaemia (CLL).  The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human… Read More

#News #Regulatory

Blood cancer
#Blood cancer #Funding #Haematology #Leukaemia #Washington University School of Medicine

$10.8 million grant supports leukaemia drug discovery projects

Washington University School of Medicine in St Louis has been awarded a five-year $10.8 million grant to further its programmes in leukaemia and other blood cancers.  The grant, from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), renews funding for the Specialized Program of Research Excellence… Read More

#Business & Investment #News

CAR-T cells attack cancer cells
#Autolus #Blood cancer #CAR-T #Cell therapy #Leukaemia #Oncology #University College London

Next-generation therapy overcomes limitations of other CAR-T

A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL).  The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More

#Cancer Research #Editor's Choice #News

CAR-T therapy for leukaemia
#Autolus #CAR-T #Cell therapy #FDA #Immunotherapy #Leukaemia #Oncology

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More

#News #Regulatory #Trending News

CAR-T therapy
#Blood cancer #Leukaemia #National Institute for Health and Care Excellence (NICE) #Oncology #Paediatrics

UK’s NICE supports CAR-T for young people with leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kymriah (tisagenlecleucel) for treating paediatric and young adults up to the age of 25 with B-cell acute lymphoblastic leukaemia (ALL). It is approved in cancers that are refractory, in relapse post-transplant or in second or later relapse. The… Read More

#News #Regulatory

CAR-T therapy
#Blood cancer #Bristol Myers Squibb #CAR-T #Cell therapy #FDA #Leukaemia #Oncology

FDA approves first CAR-T cell therapy for relapsed CLL or SLL

The US Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is approved in adult patients who have received at least two… Read More

#News #Regulatory #Trending News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

New DDW Highlights podcast: 29 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the same week that it was revealed that breast cancer was the most… Read More

#News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

This week in drug discovery (22-26 January) 

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal,… Read More

#News

Acute lymphoblastic leukemia
#Blood cancer #Eli Lilly #FDA #Leukaemia #Oncology

FDA approves second indication for Lilly’s BTK inhibitor Jaypirca

Eli Lilly’s Jaypirca (pirtobrutinib) has been approved in the US for lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). It has been granted approval by the Food and Drug Administration (FDA) to treat patients who have received at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and… Read More

#News #Regulatory